Table 1 Stakeholder groups in the study
Stakeholder fields | Expected quantity | Recruitment methods |
|---|---|---|
CM/integrated Chinese and Western medicine | 15–20 | (1) The identification of stakeholders begins with a preliminary list of experts and patients |
Clinical pharmacy | 4–6 | (2) The preliminary list will be augmented with authors of studies included in the systematic review |
Clinical epidemiology | 4–6 | |
(3) Stakeholders will recommend whomever else they think should be included as a relevant stakeholder | ||
Statistics | 4–6 | |
(4) An email will be sent to the identified panelists who registered with informed consents to explain this study and the importance of the Delphi survey | ||
Patients | 15–20 | |
Editors of important relevant journals | 4–6 | Editors from important relevant journals on hyperlipidemia will be invited via email |